NEW YORK (AP) — Drugmaker Teva Pharmaceutical Industries Ltd. said Wednesday that one of the patents on Azilect, its Parkinson’s disease drug, has been extended by five years into 2017. The Israeli company said the U.S. Patent Office granted the extension. The patent had been scheduled to expire on Feb. 7, 2012, paving the way for competition from low-cost generic versions. The patent is now set to expire Feb. 7, 2017. In 2008, worldwide sales of Azilect totaled $175 million. Teva shares rose 85 cents to $44.69 in afternoon trading.